Cargando…

Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

The monoclonal antibody (MAb) G250 binds to a tumour-associated antigen, expressed in renal cell carcinoma (RCC), which has been demonstrated to be a suitable target for antibody-mediated immunotherapy. A bispecific antibody having both G250 and anti-CD3 specificity can cross-link G250 antigen-expre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luiten, R. M., Coney, L. R., Fleuren, G. J., Warnaar, S. O., Litvinov, S. V.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1996
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074712/ https://www.ncbi.nlm.nih.gov/pubmed/8795576

Ejemplares similares

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
por: Bleumer, I, et al.
Publicado: (2004)

Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.
por: Bosslet, K., et al.
Publicado: (1991)

Monoclonal Antibodies as Tools to Combat Fungal Infections
por: Ulrich, Sebastian, et al.
Publicado: (2020)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
por: Oosterwijk-Wakka, Jeannette C., et al.
Publicado: (2013)

The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.
por: Velders, M. P., et al.
Publicado: (1998)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

B-cell display-based one-step method to generate chimeric human IgG monoclonal antibodies
por: Lin, Waka, et al.
Publicado: (2011)

Construction and expression of a human/mouse chimeric CD19 monoclonal antibody: Successful modification of a murine IgM to a chimeric IgG
por: XU, WEIQUN, et al.
Publicado: (2014)

The application of mathematical modelling to the design of bispecific monoclonal antibodies
por: van Steeg, Tamara J., et al.
Publicado: (2016)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer
por: Wang, Lei, et al.
Publicado: (2022)

Multimodal Imaging and Detection Strategy With 124 I-Labeled Chimeric Monoclonal Antibody cG250 for Accurate Localization and Confirmation of Extent of Disease During Laparoscopic and Open Surgical Resection of Clear Cell Renal Cell Carcinoma
por: Povoski, Stephen P., et al.
Publicado: (2013)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.
por: Bruynck, A., et al.
Publicado: (1993)

Generation of bispecific antibodies by structure-guided redesign of IgG constant regions
por: Iwasaki, Yordkhwan W., et al.
Publicado: (2023)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome
por: Corti, Davide, et al.
Publicado: (2016)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
por: Miyao, Kotaro, et al.
Publicado: (2023)

T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape
por: Dai, Zhenyu, et al.
Publicado: (2022)

Therapeutic Effect of Ansamitocin Targeted to Tumor by a Bispecific Monoclonal Antibody
por: Okamoto, Kayoko, et al.
Publicado: (1992)

Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
por: Tazzari, P. L., et al.
Publicado: (1993)

In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
por: Negri, D. R., et al.
Publicado: (1995)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

Targeting of Tetraspanin CD81 with Monoclonal Antibodies and Small Molecules to Combat Cancers and Viral Diseases
por: Bailly, Christian, et al.
Publicado: (2023)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

YEAST SURFACE DISPLAY OF FULL-LENGTH IGG FOR ENGINEERING MONOCLONAL AND BISPECIFIC ANTIBODIES
por: Jiang, Youwei
Publicado: (2023)

Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG
por: Fischer, Nicolas, et al.
Publicado: (2015)

Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
por: Ormhøj, Maria, et al.
Publicado: (2022)

Generation and characterization of monospecific and bispecific hexavalent trimerbodies
por: Blanco-Toribio, Ana, et al.
Publicado: (2013)

Human generation times across the past 250,000 years
por: Wang, Richard J., et al.
Publicado: (2023)

Bispecific Antibody‐directed Antitumor Activity of Human CD4(+) Helper/Killer T Cells Induced by Anti–CD3 Monoclonal Antibody plus Interleukin 2
por: Nishimura, Takashi, et al.
Publicado: (1991)

Tethered-variable C(L) bispecific IgG: an antibody platform for rapid bispecific antibody screening
por: Kim, Hok Seon, et al.
Publicado: (2017)

Epithelial Cell Adhesion Molecule (Ep-CAM) Modulates Cell–Cell Interactions Mediated by Classic Cadherins
por: Litvinov, Sergey V., et al.
Publicado: (1997)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Becker, Scott A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jeqls6nt8tl1mjag0b290kvhj1